Integrated research site organisation Velocity Clinical Research has announced the acquisition of multi-site company Egin Research, marking its expansion into the UK.

With the expansion into Europe, Velocity now has 42 dedicated research locations.

The addition of the two sites of Egin Research increases Velocity’s site footprint in Europe to three, following its first purchase in Hamburg, Germany, in July this year.

Velocity Clinical Research Europe executive vice-president Dominic Clavell said: “The size and importance of the UK market for clinical research cannot be underestimated. There is a focus on clinical trial regulation reform in a post-Brexit era to bring new treatments to patients faster.

“The region significantly contributed to Covid vaccine research, leading to the UK Government’s recent £800m cash injection into the clinical trials industry to boost innovation, growth, and patient safety.”

Egin Research has plans for continued growth as it integrates into the global network of Velocity.

With Velocity’s support, the company will expand its therapeutic areas for recruiting patients into clinical trials for some acute diseases, and all ambulatory chronic diseases. 

Through a centralised infrastructure and common technology backbone, Velocity’s sites are completely owned and fully integrated.

This allows for superior patient enrolment and the consistent delivery of data.

As a result, simplified access to international clinical research provides benefits for clinical research organisations and big pharmaceutical companies.

Egin Research chief investigator Dr Ahmed Elshashai said: “We strive to provide the best experience for participants by considering their involvement in clinical trials as a journey that we go through together.”

In June this year, Velocity signed an exclusive research partnership with Coastal Heart Medical Group to transform specialty care by applying its integrated multi-site approach.